The use of ROX index to predict failure of high-flow nasal cannula in patients with COVID-19 associated acute respiratory distress syndrome.

Completed

• Conditions: Patients with mild- to moderate COVID-19-associated acute respiratory distress syndrome (ARDS) can be treated with high-flow nasal cannula (HFNC).; COVID-19 associated acute respiratory distress syndrome; high-flow nasal cannula; HFNC failure; ROX index; prediction

• Registration Number: TCTR20230206002
• Lead Sponsor: The Research Fund of the Faculty of Medicine Vajira Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-01-31
• Study Start: 2023-02-06
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 212

Inclusion Criteria

1. Patients aged 18 or older.
2. Patients with confirmed diagnosis of COVID-19 infection using a positive for reverse transcription polymerase chain reaction (RT-PCR)
3. Bilateral infiltration in chest radiography
4. Started HFNC therapy during hospitalization.

Exclusion Criteria

1. Patients who initiated IMV before commencing HFNC therapy.
2. Patients with signed a do-not-resuscitate advance medical directive.
3. Patients who transferred to another hospital during HFNC therapy.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HFNC failure During HFNC therapy Yes/No

Secondary Outcome Measures

Name	Time	Method
n/a n/a n/a